Dn B Asset Management As Gilead Sciences, Inc. Transaction History

Dn B Asset Management As

$19.9 Billion
Q2 2024

A detailed history of Dn B Asset Management As transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Dn B Asset Management As holds 290,803 shares of GILD stock, worth $22.9 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

290,803

Previous 197,638 47.14%

Holding current value

$22.9 Million

Previous $14.5 Million 37.82%

% of portfolio

0.1%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 05, 2024	BUY	$63.15 - $72.88 $5.88 Million - $6.79 Million	93,165 Added 47.14%	290,803 $20 Million
Q1 2024 Apr 12, 2024	SELL	$71.58 - $87.29 $3.86 Million - $4.71 Million	-53,988 Reduced 21.46%	197,638 $14.5 Million
Q4 2023 Jan 04, 2024	SELL	$73.27 - $83.09 $4.3 Million - $4.88 Million	-58,703 Reduced 18.92%	251,626 $20.4 Million
Q3 2023 Oct 13, 2023	BUY	$73.94 - $80.67 $178,712 - $194,979	2,417 Added 0.78%	310,329 $23.3 Million
Q2 2023 Jul 06, 2023	SELL	$76.01 - $86.7 $587,177 - $669,757	-7,725 Reduced 2.45%	307,912 $23.7 Million
Q1 2023 Apr 20, 2023	SELL	$77.31 - $88.08 $507,694 - $578,421	-6,567 Reduced 2.04%	315,637 $26.2 Million
Q4 2022 Jan 12, 2023	SELL	$62.32 - $89.47 $312,223 - $448,244	-5,010 Reduced 1.53%	322,204 $27.7 Billion
Q3 2022 Oct 11, 2022	SELL	$59.54 - $68.01 $3.44 Million - $3.93 Million	-57,724 Reduced 15.0%	327,214 $20.2 Million
Q2 2022 Jul 08, 2022	SELL	$57.72 - $65.01 $1.2 Million - $1.36 Million	-20,854 Reduced 5.14%	384,938 $23.8 Billion
Q1 2022 Apr 08, 2022	BUY	$57.92 - $72.58 $3.4 Million - $4.26 Million	58,670 Added 16.9%	405,792 $24.1 Million
Q4 2021 Jan 12, 2022	BUY	$64.88 - $73.64 $1.97 Million - $2.23 Million	30,308 Added 9.57%	347,122 $25.2 Million
Q3 2021 Oct 15, 2021	SELL	$67.69 - $73.03 $44,066 - $47,542	-651 Reduced 0.21%	316,814 $22.1 Million
Q2 2021 Jul 06, 2021	BUY	$63.47 - $69.35 $451,652 - $493,494	7,116 Added 2.29%	317,465 $21.9 Billion
Q1 2021 Apr 15, 2021	SELL	$60.0 - $68.46 $73.4 Million - $83.7 Million	-1,223,144 Reduced 79.76%	310,349 $20.1 Million
Q4 2020 Jan 19, 2021	SELL	$56.65 - $64.55 $16.3 Million - $18.6 Million	-288,155 Reduced 15.82%	1,533,493 $89.3 Million
Q3 2020 Oct 14, 2020	BUY	$62.1 - $78.08 $92 Million - $116 Million	1,481,374 Added 435.35%	1,821,648 $115 Million
Q2 2020 Jul 08, 2020	BUY	$72.34 - $84.0 $4.29 Million - $4.98 Million	59,282 Added 21.1%	340,274 $26.2 Billion
Q1 2020 Apr 17, 2020	BUY	$62.63 - $80.22 $6.77 Million - $8.67 Million	108,091 Added 62.52%	280,992 $21 Million
Q4 2019 Jan 13, 2020	SELL	$61.62 - $67.78 $3.43 Million - $3.78 Million	-55,705 Reduced 24.37%	172,901 $11.2 Million
Q3 2019 Oct 16, 2019	SELL	$62.51 - $69.0 $5.49 Million - $6.06 Million	-87,820 Reduced 27.75%	228,606 $14.5 Million
Q2 2019 Jul 08, 2019	BUY	$61.87 - $69.38 $1.59 Million - $1.78 Million	25,719 Added 8.85%	316,426 $0
Q1 2019 Apr 11, 2019	SELL	$62.53 - $70.05 $1.88 Million - $2.11 Million	-30,086 Reduced 9.38%	290,707 $0
Q4 2018 Jan 15, 2019	BUY	$60.54 - $79.0 $2.06 Million - $2.68 Million	33,981 Added 11.85%	320,793 $20.1 Million
Q3 2018 Oct 10, 2018	BUY	$71.28 - $78.92 $9.28 Million - $10.3 Million	130,260 Added 83.21%	286,812 $0
Q2 2018 Jul 06, 2018	BUY	$64.88 - $75.68 $428,207 - $499,488	6,600 Added 4.4%	156,552 $0
Q1 2018 Apr 11, 2018	BUY	$72.84 - $88.8 $954,204 - $1.16 Million	13,100 Added 9.57%	149,952 $0
Q4 2017 Jan 10, 2018	BUY	$71.15 - $83.52 $168,625 - $197,942	2,370 Added 1.76%	136,852 $0
Q3 2017 Oct 11, 2017	BUY	$72.11 - $85.47 $9.7 Million - $11.5 Million	134,482	134,482 $0

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $98.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Gilead Sciences, Inc. Transaction History